Vericel Stock Forecast, Price & News

+0.64 (+1.10 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $58.62
50-Day Range
MA: $51.11
52-Week Range
Now: $58.62
Volume515,169 shs
Average Volume910,870 shs
Market Capitalization$2.70 billion
P/E RatioN/A
Dividend YieldN/A
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:VCEL
Year FoundedN/A



Sales & Book Value

Annual Sales$117.85 million
Cash Flow$0.32 per share
Book Value$2.49 per share


Net Income$-9,660,000.00


Market Cap$2.70 billion
Next Earnings Date5/4/2021 (Estimated)


-$0.06 EPS Expected for Vericel Co. (NASDAQ:VCEL) This Quarter
April 14, 2021 |
Vericel (NASDAQ:VCEL) Trading Down 6.8%
April 9, 2021 |
Vericel (NASDAQ:VCEL) Hits New 52-Week High at $60.15
April 8, 2021 |
Vericel (NASDAQ:VCEL) Trading Down 4.2% After Insider Selling
April 1, 2021 |
Vericel Reaches Analyst Target Price - Nasdaq
March 22, 2021 |
Why Vericel Stock Raced 13% Higher on Thursday
March 18, 2021 |
See More Headlines


Overall MarketRank

1.11 out of 5 stars

Medical Sector

992nd out of 2,025 stocks

Biological Products, Except Diagnostic Industry

129th out of 177 stocks

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.64 (+1.10 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Vericel (NASDAQ:VCEL) Frequently Asked Questions

Is Vericel a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel
or view top-rated stocks.

What stocks does MarketBeat like better than Vericel?

Wall Street analysts have given Vericel a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vericel wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vericel?

Vericel saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 62.5% from the March 15th total of 3,010,000 shares. Based on an average daily trading volume, of 942,600 shares, the short-interest ratio is presently 5.2 days.
View Vericel's Short Interest

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Vericel

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.05. The biotechnology company earned $45.23 million during the quarter, compared to analysts' expectations of $45.05 million. Vericel had a net margin of 0.12% and a trailing twelve-month return on equity of 0.13%.
View Vericel's earnings history

How has Vericel's stock been impacted by COVID-19 (Coronavirus)?

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCEL shares have increased by 385.3% and is now trading at $58.62.
View which stocks have been most impacted by COVID-19

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $161-164 million, compared to the consensus revenue estimate of $157.03 million.

What price target have analysts set for VCEL?

8 equities research analysts have issued 1 year target prices for Vericel's shares. Their forecasts range from $31.00 to $60.00. On average, they anticipate Vericel's share price to reach $49.00 in the next twelve months. This suggests that the stock has a possible downside of 16.4%.
View analysts' price targets for Vericel
or view top-rated stocks among Wall Street analysts.

Who are Vericel's key executives?

Vericel's management team includes the following people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 57, Pay $1.19M)
  • Mr. Michael Halpin, Chief Operating Officer (Age 60, Pay $585.43k)
  • Ms. Sandra Pennell, VP, Principal Accounting Officer & Controller (Age 41, Pay $276.92k)
  • Mr. Sean C. Flynn, VP, Gen. Counsel & Sec. (Age 47, Pay $502.69k)
  • Dr. Jonathan M. Hopper, Chief Medical Officer (Age 59, Pay $523.68k)
  • Mr. Joseph Anthony Mara Jr., CFO & Treasurer (Age 45)
  • Ms. Heidi Hassen, VP of HR
  • Mr. Roland DeAngelis, Sr. VP of Commercial Operations

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel CEO Nick Colangelo on Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.92%), Calamos Advisors LLC (0.35%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%), Mesirow Financial Investment Management Inc. (0.03%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Robert L Md Zerbe and Steven C Gilman.
View institutional ownership trends for Vericel

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Mesirow Financial Investment Management Inc., and Pacer Advisors Inc.. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, and Robert L Md Zerbe.
View insider buying and selling activity for Vericel
or view top insider-selling stocks.

Which institutional investors are buying Vericel stock?

VCEL stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Scout Investments Inc., Louisiana State Employees Retirement System, Crossmark Global Holdings Inc., and Everence Capital Management Inc..
View insider buying and selling activity for Vericel
or or view top insider-buying stocks.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $58.62.

How much money does Vericel make?

Vericel has a market capitalization of $2.70 billion and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does Vericel have?

Vericel employs 273 workers across the globe.

What is Vericel's official website?

The official website for Vericel is

Where are Vericel's headquarters?

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.